What is the dosing for gabapentin (Neurontin) for postherpetic neuralgia (PHN) in shingles?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Gabapentin Dosing for Postherpetic Neuralgia in Shingles

For postherpetic neuralgia, gabapentin should be initiated at 300 mg on day 1,600 mg/day (300 mg twice daily) on day 2, and 900 mg/day (300 mg three times daily) on day 3, with subsequent titration up to 1800 mg/day as needed for pain relief. 1

Initial Dosing and Titration Schedule

  • Start with 300 mg on day 1 as a single dose 1
  • Increase to 600 mg/day (300 mg twice daily) on day 2 1
  • Increase to 900 mg/day (300 mg three times daily) on day 3 1
  • Subsequently titrate up as needed for pain relief to a maximum of 1800 mg/day (600 mg three times daily) 1, 2

Effective Dose Range

  • Clinical efficacy has been demonstrated across a dose range from 1800 mg/day to 3600 mg/day 1
  • However, additional benefit of using doses greater than 1800 mg/day has not been demonstrated in clinical studies 1, 2
  • The maximum time between doses should not exceed 12 hours to maintain therapeutic effect 1

Dosage Adjustment in Special Populations

Renal Impairment

  • For patients with creatinine clearance 30-59 mL/min: 400-1400 mg/day in divided doses 1
  • For patients with creatinine clearance 15-29 mL/min: 200-700 mg/day in divided doses 1
  • For patients with creatinine clearance <15 mL/min: 100-300 mg/day as a single daily dose 1

Elderly Patients

  • Start with lower doses and titrate more slowly due to decreased renal function 1, 3
  • Consider starting at 100-300 mg at bedtime and increase gradually 3, 2

Efficacy and Evidence

  • Gabapentin has demonstrated efficacy for postherpetic neuralgia with a number needed to treat (NNT) of 4.39 3
  • In randomized controlled trials, gabapentin significantly reduced pain from 6.3 to 4.2 points compared to minimal change with placebo (6.5 to 6.0) 4
  • Gabapentin also improves sleep interference and quality of life measures in patients with postherpetic neuralgia 4

Common Side Effects and Management

  • Most common adverse effects include somnolence, dizziness, ataxia, and peripheral edema 4
  • Side effects can be minimized by:
    • Starting with lower doses 3, 2
    • Gradual titration at weekly intervals 3
    • Taking medication with food to reduce gastrointestinal effects 5

Alternative Formulations

  • Once-daily gastroretentive formulations are available that may improve adherence and reduce side effects through gradual release 6
  • These formulations may have a lower incidence of dizziness and somnolence compared to three-times-daily dosing 6

Treatment Duration and Monitoring

  • An adequate trial of gabapentin treatment may require 2 months or more 3
  • Regular assessment of pain relief, functional improvement, and side effects should guide continued therapy 2
  • If inadequate response after 8 weeks at maximum tolerated dose, consider alternative or adjunctive therapy 3, 7

Alternative Options if Gabapentin Fails

  • Pregabalin may be considered if patients have inadequate response to gabapentin 3
  • Tricyclic antidepressants show excellent efficacy (NNT = 2.64) and may be used as alternatives 3
  • Topical lidocaine patches (5%) provide excellent efficacy (NNT = 2) with minimal systemic effects 2

Gabapentin remains a first-line treatment for postherpetic neuralgia with established efficacy and a manageable side effect profile when properly titrated.

References

Guideline

Treatment Options for Post-Herpetic Neuralgia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

The management of postherpetic neuralgia.

Postgraduate medical journal, 1997

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.